7.29

1.53% 0.11

After Hours: 7.17 -0.12 -1.65%

Wave Life Sciences Ltd (WVE)

Overview News Price History Option Chain Financials Why WVE Down? Discussions Forecast

Wave Life Sciences Ltd stock is traded at $7.29, with a volume of 3.98M. It is up +1.53% in the last 24 hours and up +2.82% over the past month. WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Previous Close:

$7.18

Open:

$7.24

24h Volume:

3.98M

Relative Volume:

0.96

Market Cap:

$1.40B

Revenue:

$71.80M

Net Income/Loss:

$-183.59M

P/E Ratio:

-6.9145

EPS:

-1.0543

Net Cash Flow:

$-186.52M

1W Performance:

+3.40%

1M Performance:

+2.82%

6M Performance:

-7.49%

1Y Performance:

+13.73%

1-Day Range:

$7.035

$7.3299

1-Week Range:

$6.935

$7.615

52-Week Range:

$5.02

$21.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name

Wave Life Sciences Ltd

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

617-949-2900

Address

7 STRAITS VIEW, SINGAPORE

Employee

317

Twitter

@WAVELifeSci

Next Earnings Date

2026-04-28

Latest SEC Filings

WVE's Discussions on Twitter

Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
WVE Wave Life Sciences Ltd	7.29	1.38B	71.80M	-183.59M	-186.52M	-1.0543
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-05-26	Initiated	BofA Securities	Buy
Dec-12-25	Reiterated	Wedbush	Outperform
Dec-09-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-20-25	Initiated	Wells Fargo	Overweight
Aug-04-25	Initiated	Canaccord Genuity	Buy
Jul-28-25	Initiated	Oppenheimer	Outperform
Jul-16-25	Initiated	Citigroup	Buy
Jun-11-25	Resumed	Raymond James	Outperform
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Wedbush	Outperform
Feb-25-25	Initiated	Jefferies	Buy
Oct-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Sep-27-24	Resumed	JP Morgan	Overweight
Sep-19-24	Initiated	B. Riley Securities	Buy
Sep-09-24	Initiated	JP Morgan	Overweight
May-15-24	Initiated	Wells Fargo	Overweight
Dec-19-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Raymond James	Outperform
May-24-23	Downgrade	Jefferies	Buy → Hold
Dec-15-20	Resumed	H.C. Wainwright	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Dec-31-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-01-19	Initiated	Guggenheim	Buy
Jul-15-19	Initiated	Cowen	Market Perform
Apr-17-19	Reiterated	H.C. Wainwright	Buy
Aug-07-18	Initiated	Stifel	Buy
Jul-23-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Reiterated	Mizuho	Buy
Feb-15-17	Initiated	H.C. Wainwright	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Dec-07-15	Initiated	JMP Securities	Mkt Outperform
Dec-07-15	Initiated	Jefferies	Buy
Dec-07-15	Initiated	Leerink Partners	Outperform
Dec-07-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Wave Life Sciences Ltd Stock (WVE) Latest News

11:40 AM

FMR LLC takes 2.8% position in Wave Life Sciences (NASDAQ: WVE) - Stock Titan

11:40 AM

May 03, 2026

Wave Life Sciences to present WVE-006 trial data at ATS - Investing.com

May 03, 2026

May 02, 2026

Pictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVE - MarketBeat

May 02, 2026

A Look At Wave Life Sciences (WVE) Valuation After Q1 2026 Results And RNA Pipeline Progress - simplywall.st

May 02, 2026

WAVE Life Sciences (NASDAQ:WVE) Upgraded to "Hold" at Wall Street Zen - MarketBeat

May 02, 2026

WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

May 02, 2026

May 01, 2026

Wave Life Sciences (NASDAQ: WVE) proposes one‑for‑one redomiciliation to Delaware - Stock Titan

May 01, 2026

Wave Life Sciences 2025 Executive Compensation, Governance, and Business Highlights – 10-K/A Report - Minichart

May 01, 2026

MSN Money - MSN

May 01, 2026

Apr 30, 2026

Canaccord lowers Wave Life Sciences stock price target on valuation By Investing.com - Investing.com India

Apr 30, 2026

WVE Maintained by Canaccord Genuity -- Price Target Lowered to $43.00 - GuruFocus

Apr 30, 2026

Wave Life Sciences Signals Momentum In Earnings Call - The Globe and Mail

Apr 30, 2026

Wave Life Sciences : Amendment to Annual Report (Form 10-K/A) - marketscreener.com

Apr 30, 2026

Wave Life Sciences (Nasdaq: WVE) details 2025 milestones, cash and executive pay - Stock Titan

Apr 30, 2026

Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2026 Earnings Call Transcript - Insider Monkey

Apr 30, 2026

B. Riley Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $31 - Moomoo

Apr 30, 2026

A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $43 - Moomoo

Apr 30, 2026

Canaccord lowers Wave Life Sciences stock price target on valuation - Investing.com

Apr 30, 2026

WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 30, 2026

Does Strong Q1 2026 Beat and Narrower Loss Reshape The Bull Case For Wave Life Sciences (WVE)? - simplywall.st

Apr 30, 2026

Apr 29, 2026

Duchenne Muscular Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Vertex Pharma, Bioleaders Corp., Wave Life Sciences, REGENXBIO - Barchart.com

Apr 29, 2026

RBC Capital Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15 - Moomoo

Apr 29, 2026

WAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6%Here's What Happened - MarketBeat

Apr 29, 2026

B. Riley Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $31 - Moomoo

Apr 29, 2026

WAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat

Apr 29, 2026

WVE Maintained by Truist Securities -- Price Target Lowered to $15 - GuruFocus

Apr 29, 2026

A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $36 - Moomoo

Apr 29, 2026

Truist Financial Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $15 - Moomoo

Apr 29, 2026

Wave Life Sciences Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance

Apr 29, 2026

Wave Life Sciences: Q1 Earnings Snapshot - theheraldreview.com

Apr 29, 2026

Truist assumes coverage on Wave Life Sciences stock with buy rating - Investing.com India

Apr 29, 2026